Capricor Therapeutics stock experienced a significant decline after the release of FDA briefing documents. The documents appear to have negatively impacted investor sentiment regarding the company's prospects.
Capricor Therapeutics Stock Falls Following FDA Briefing Documents
|1 min read
Capricor TherapeuticsBiotechnologyFDARegulatory NewsStock Decline
